Generic Drugs Market - Global Industry Analysis, Market Size, Share, Growth, Trends, Region Outlook, And Segment Forecasts, 2022 - 2030

The global generic drugs market size is expected to hit around USD 670.82 billion by 2030 and poised to grow at a CAGR of 5.4% from 2022 to 2030.

Generic Drugs Market Size 2022 to 2030

Generic drugs refer to the drugs with a chemical make-up of a drug a like an existing branded drug. These medications are inexpensive and similar to branded drugs in power, and route of delivery, consistency, efficiency, and usage. These are subject to administration regulations in different nations, rather than associated with a particular company. These drugs are proven to be as safe and effective as their brand name formulation, which has already been marketed. While other features, such as color, form and flavoring that do not influence the health and efficacy of pharmaceutical products that vary from the original edition; generic versions are formulated with the same active ingredients as their advertised counterparts when operating in the same manner and quantity of the time.

The low price of generic drugs as substitute to branded drugs is the supreme crucial factor in the growth of the global market for generic drugs. Generic drug firms do not have to experience high drug improvement costs and so cost is 85% less than branded drugs. The costs of research and development, as well as drug discovery, are not included in the case of generic drugs. A very small amount is to be invested in the collection of pre-marketing data for generic medicines. The companies rely on the clinical evidence provided by the business of the innovators for the health and effectiveness of the drug. In addition, generic drug claimants do not need to repeat the animal and clinical (human) studies needed to demonstrate the safety and efficacy of brand name medicines. As a result, generic drugs, with similar active ingredients having the same strength, stability, purity, effectiveness and protection as branded drugs, are available at a lower price than branded drugs. Such advantages lead patients to opt for generics as alternatives to costly branded medications. Increasing number of patent expired branded drugs is another major factor expected to boost growth of the target market in the near future. Drug prices decline considerably when patents expire. The degree of price reduction varied critically between products and nations. Increasing prevalence of chronic diseases, diabetes & cardiovascular diseases are creating huge demand for the drugs. However, the numbers of patent expired branded drugs is constantly increasing in the North America region which is providing huge potential opportunities to the generic drugs industry as the generic drugs offer various advantages over the non-generic drugs. For instance in 2019 FDA approved approximately 108 generic patents only in U.S.A.

Report Highlights:

  • On the basis of drug type, simple generic drugs segment is expected hold largest revenue share in the forecast period of time 2021-2030. This growth is mostly attributed to low cost associated with the generic drugs over super generic drugs. Further super generics of drug type segment are expected to resister noteworthy growth rate over the forecast period.
  • On the basis of therapeutic application, oncology therapeutic application segment accounted for the largest revenue with weighty share in 2020. This is attributed to increasing demand for the treatment of oncology disorders worldwide. The cardiovascular segment is anticipated to grow at reasonable CAGR over the forecast period.
  • Teva Pharmaceutical Industries Ltd. foremost player in the global industry estimated for the remarkable share of the global market. The growth is accredited to various commercial strategies adopted by the company.

Regional Analysis:

The report covers data for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2020, North America conquered the global market with a market share of more than 30%. U.S. signified as the highest share holding country in the North America region primarily due to advanced healthcare infrastructure, increasing prevalence of chronic diseases, and presence of leading layers in the countries of the North America. Asia Pacific generic drugs industry market is estimated to grow at noteworthy rate of growth in the next 10 years. The China generic drugs industry market is anticipated to dominate in terms of revenue in the Asia Pacific region. Increasing the prevalence of chronic diseases among the population along with increasing initiatives by the regulatory bodies to control them in the countries of the region is a main driver growth of the APAC. Nevertheless, emerging markets in the AAC region is creating growth opportunities in the target market.

Top Players contending in the Market:

The companies focusing on research and development are expected to lead the global generic drugs market. Leading competitors contending in global generic drugs market are as follows:

  • Mylan N.V.
  • Abbott Laboratories
  • ALLERGAN
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • STADA Arzneimittel AG
  • GlaxoSmithKline Plc.
  • Baxter International Inc.
  • Pfizer Inc.
  • Sandoz International GmbH

Major Market Segments Covered:

By Drug Type

  • Simple Generics
    • Super Generics

By Brand

  • Pure generic drugs
    • Branded generic drugs

By Route of Drug Administration

  • Oral
    • Topical
    • Parental
    • Others

By Therapeutic Application

  • Central nervous system (CNS)
  • Cardiovascular
  • Dermatology
  • Oncology
  • Respiratory
  • Others

Key Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Others

By Geography

  • North America
      • U.S.
      • Canada
  • Europe
      • Germany
      • France
      • United Kingdom
      • Rest of Europe
  • Asia Pacific
      • China
      • Japan
      • India
      • Southeast Asia
      • Rest of Asia Pacific
  • Latin America
      • Brazil
      • Rest of Latin America
  • Middle East & Africa (MEA)
      • GCC
      • North Africa
      • South Africa
      • Rest of Middle East & Africa

 

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Generic Drugs Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Generic Drugs Market

5.1. Covid-19: generic drugs Industry Impact
5.2. generic drugs Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and generic drugs Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for generic drugs Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Generic Drugs Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. The low cost of generics, as an alternative to branded drugs
6.1.1.2. Large number of patent expired branded drugs
6.1.1.3. Initiatives by governments and other regulatory bodies
6.1.2. Market Restraints
6.1.2.1. Stringent governmental regulations and adverse effects associated with drugs
6.1.3. Market Opportunities
6.1.3.1. Use of RPA to ensure regulatory and standards compliance

Chapter 7. Global Generic Drugs Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. generic drugs Market Revenue by Market Players (2017 - 2020)
7.1.1.2. generic drugs Market Revenue Market Share by Market Players (2017 - 2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Generic Drugs Market, By Drug Type

8.1. generic drugs Market, by Drug Type, 2017-2027
8.1.1. Simple Generics
8.1.1.1. Market Revenue and Forecast (2017-2027)
8.1.2. Super Generics
8.1.2.1. Market Revenue and Forecast (2017-2027)

Chapter 9. Global Generic Drugs Market, By Brand

9.1. generic drugs Market, by Brand, 2017-2027
9.1.1. Pure generic drugs
9.1.1.1. Market Revenue and Forecast (2017-2027)
9.1.2. Branded generic drugs
9.1.2.1. Market Revenue and Forecast (2017-2027)

Chapter 10. Global Generic Drugs Market, By Route of Drug Administration

10.1. generic drugs Market, by Route of Drug Administration, 2017-2027
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2027)
10.1.2. Topical
10.1.2.1. Market Revenue and Forecast (2017-2027)
10.1.3. Parental
10.1.3.1. Market Revenue and Forecast (2017-2027)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2027)

Chapter 11. Global Generic Drugs Market, By Therapeutic Application

11.1. generic drugs Market, by Therapeutic Application, 2017-2027
11.1.1. Central nervous system (CNS)
11.1.1.1. Market Revenue and Forecast (2017-2027)
11.1.2. Cardiovascular
11.1.2.1. Market Revenue and Forecast (2017-2027)
11.1.3. Dermatology
11.1.3.1. Market Revenue and Forecast (2017-2027)
11.1.4. Oncology
11.1.4.1. Market Revenue and Forecast (2017-2027)
11.1.5. Respiratory
11.1.5.1. Market Revenue and Forecast (2017-2027)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2017-2027)

Chapter 12. Global Generic Drugs Market, By Distribution Channel

12.1. generic drugs Market, by Distribution Channel, 2017-2027
12.1.1. Hospitals Pharmacies
12.1.1.1. Market Revenue and Forecast (2017-2027)
12.1.2. Retail Pharmacies
12.1.2.1. Market Revenue and Forecast (2017-2027)
12.1.3. Others
12.1.3.1. Market Revenue and Forecast (2017-2027)

Chapter 13. Global Generic Drugs Market, Regional Estimates and Trend Forecast

13.1. North America
13.1.1. Market Revenue Forecast by Drug Type(2017-2027)
13.1.2. Market Revenue Forecast by Brand (2017-2027)
13.1.3. Market Revenue Forecast by Route of Drug Administration (2017-2027)
13.1.4. Market Revenue Forecast by Therapeutic Application (2017-2027)
13.1.5. Market Revenue Forecast by Distribution Channel (2017-2027)
13.1.6. U.S
13.1.6.1. Market Revenue Forecast (2017-2027)
13.1.7. Canada
13.1.7.1. Market Revenue Forecast (2017-2027)
13.2. Europe
13.2.1. Market Revenue Forecast by Drug Type (2017-2027)
13.2.2. Market Revenue Forecast by Brand (2017-2027)
13.2.3. Market Revenue Forecast by Route of Drug Administration (2017-2027)
13.2.4. Market Revenue Forecast by Therapeutic Application (2017-2027)
13.2.5. Market Revenue Forecast by Distribution Channel (2017-2027)
13.2.6. UK
13.2.6.1. Market Revenue Forecast (2017-2027)
13.2.7. Germany
13.2.7.1. Market Revenue Forecast (2017-2027)
13.2.8. France
13.2.8.1. Market Revenue Forecast (2017-2027)
13.2.9. Rest of EU
13.2.9.1. Market Revenue Forecast (2017-2027)
13.3. Asia Pacific (APAC)
13.3.1. Market Revenue Forecast by Drug Type (2017-2027)
13.3.2. Market Revenue Forecast by Brand (2017-2027)
13.3.3. Market Revenue Forecast by Route of Drug Administration (2017-2027)
13.3.4. Market Revenue Forecast by Therapeutic Application (2017-2027)
13.3.5. Market Revenue Forecast by Distribution Channel (2017-2027)
13.3.6. China
13.3.6.1. Market Revenue Forecast (2017-2027)
13.3.7. India
13.3.7.1. Market Revenue Forecast (2017-2027)
13.3.8. Japan
13.3.8.1. Market Revenue Forecast (2017-2027)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue Forecast (2017-2027)
13.4. LATAM
13.4.1. Market Revenue Forecast by Drug Type (2017-2027)
13.4.2. Market Revenue Forecast by Brand (2017-2027)
13.4.3. Market Revenue Forecast by Route of Drug Administration (2017-2027)
13.4.4. Market Revenue Forecast by Therapeutic Application (2017-2027)
13.4.5. Market Revenue Forecast by Distribution Channel (2017-2027)
13.4.6. Brazil
13.4.6.1. Market Revenue Forecast (2017-2027)
13.4.7. Rest of LATAM
13.4.7.1. Market Revenue Forecast (2017-2027)
13.5. Middle East and Africa (MEA)
13.5.1. Market Revenue Forecast by Drug Type (2017-2027)
13.5.2. Market Revenue Forecast by Brand (2017-2027)
13.5.3. Market Revenue Forecast by Route of Drug Administration (2017-2027)
13.5.4. Market Revenue Forecast by Therapeutic Application (2017-2027)
13.5.5. Market Revenue Forecast by Distribution Channel (2017-2027)
13.5.6. GCC
13.5.6.1. Market Revenue Forecast (2017-2027)
13.5.7. North Africa
13.5.7.1. Market Revenue Forecast (2017-2027)
13.5.8. South Africa
13.5.8.1. Market Revenue Forecast (2017-2027)
13.5.9. Rest of MEA
13.5.9.1. Market Revenue Forecast (2017-2027)

Chapter 14. Company Profiles

14.1. Abbott Laboratories
14.1.1. Company Overview, Business Information, Regional Presence
14.1.2. Product Portfolio Analysis
14.1.2.1. Product Details, Specification, Application
14.1.3. Revenue, Price, and Gross Margin (2017-2020)
14.1.4. Recent Developments and Strategies
14.2. Teva Pharmaceutical Industries Ltd.
14.2.1. Company Overview, Business Information, Regional Presence
14.2.2. Product Portfolio Analysis
14.2.2.1. Product Details, Specification, Application
14.2.3. Revenue, Price, and Gross Margin (2017-2020)
14.2.4. Recent Developments and Strategies
14.3. ALLERGAN
14.3.1. Company Overview, Business Information, Regional Presence
14.3.2. Product Portfolio Analysis
14.3.2.1. Product Details, Specification, Application
14.3.3. Revenue, Price, and Gross Margin (2017-2020)
14.3.4. Recent Developments and Strategies
14.4. Sandoz International GmbH
14.4.1. Company Overview, Business Information, Regional Presence
14.4.2. Product Portfolio Analysis
14.4.2.1. Product Details, Specification, Application
14.4.3. Revenue, Price, and Gross Margin (2017-2020)
14.4.4. Recent Developments and Strategies
14.5. Mylan N.V.
14.5.1. Company Overview, Business Information, Regional Presence
14.5.2. Product Portfolio Analysis
14.5.2.1. Product Details, Specification, Application
14.5.3. Revenue, Price, and Gross Margin (2017-2020)
14.5.4. Recent Developments and Strategies
14.6. STADA Arzneimittel AG
14.6.1. Company Overview, Business Information, Regional Presence
14.6.2. Product Portfolio Analysis
14.6.2.1. Product Details, Specification, Application
14.6.3. Revenue, Price, and Gross Margin (2017-2020)
14.6.4. Recent Developments and Strategies
14.7. Baxter International Inc.
14.7.1. Company Overview, Business Information, Regional Presence
14.7.2. Product Portfolio Analysis
14.7.2.1. Product Details, Specification, Application
14.7.3. Revenue, Price, and Gross Margin (2017-2020)
14.7.4. Recent Developments and Strategies
14.8. Eli Lilly and Company
14.8.1. Company Overview, Business Information, Regional Presence
14.8.2. Product Portfolio Analysis
14.8.2.1. Product Details, Specification, Application
14.8.3. Revenue, Price, and Gross Margin (2017-2020)
14.8.4. Recent Developments and Strategies
14.9. GlaxoSmithKline Plc.
14.9.1. Company Overview, Business Information, Regional Presence
14.9.2. Product Portfolio Analysis
14.9.2.1. Product Details, Specification, Application
14.9.3. Revenue, Price, and Gross Margin (2017-2020)
14.9.4. Recent Developments and Strategies
14.10. Pfizer Inc.
14.10.1. Company Overview, Business Information, Regional Presence
14.10.2. Product Portfolio Analysis
14.10.2.1. Product Details, Specification, Application
14.10.3. Revenue, Price, and Gross Margin (2017-2020)
14.10.4. Recent Developments and Strategies

Chapter 15. Appendix

15.1. About Us
15.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask to Expert